SRM

SRM Pharmaceuticals was a clinical-stage biopharmaceutical company primarily focused on the development of selective receptor modulators for the treatment of cancer and endocrine-related disorders. The company's research efforts were centered on identifying and developing small molecule therapeutics that could selectively target hormone receptors, such as the estrogen and androgen receptors, to treat conditions like breast and prostate cancer. Despite its clinical aspirations, the company faced significant financial and regulatory hurdles, leading to its eventual cessation of operations. SRM Pharmaceuticals is now considered an inactive entity in the biotechnology sector.